About Express Scripts (NASDAQ:ESRX)
Express Scripts, Inc. is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workersâ€™ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM). PBM segmentâ€™s services include retail network pharmacy management and retail drug card programs, home delivery services, specialty benefit services, patient care contact centers, benefit plan design and consultation, drug formulary management, compliance and therapy management programs, information reporting and analysis programs, rebate programs, and electronic claims processing and drug utilization review. EM segmentâ€™s services include distribution of pharmaceuticals and medical supplies to providers and clinics and healthcare account administration and implementation of consumer-directed healthcare solutions.
Industry, Sector and Symbol
Industry MEDICAL CARE
Sub-IndustryHealth Care Services
Trailing P/E Ratio9.15454553581806
Forward P/E Ratio7.67
Sales & Book Value
Annual Sales$100.06 billion
Price / Sales0.40
Cash Flow$10.30 per share
Price / Cash6.96
Book Value$32.00 per share
Price / Book2.24
Net Income$4.52 billion
Return on Equity25.19%
Return on Assets8.00%
Express Scripts (NASDAQ:ESRX) Frequently Asked Questions
What is Express Scripts' stock symbol?
Express Scripts trades on the NASDAQ under the ticker symbol "ESRX."
How will Express Scripts' stock buyback program work?
Express Scripts declared that its board has approved a stock repurchase program on Wednesday, December 20th 2017, which permits the company to buyback 45,000,000 shares, according to EventVestor. This buyback authorization permits the company to purchase shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company's leadership believes its stock is undervalued.
How were Express Scripts' earnings last quarter?
Express Scripts Holding (NASDAQ:ESRX) announced its earnings results on Tuesday, February, 27th. The company reported $2.16 earnings per share for the quarter, beating the consensus estimate of $2.09 by $0.07. The firm earned $25.38 billion during the quarter, compared to analyst estimates of $25.07 billion. Express Scripts had a return on equity of 25.19% and a net margin of 4.51%. The firm's quarterly revenue was up 2.1% compared to the same quarter last year. During the same period last year, the firm earned $1.88 earnings per share. View Express Scripts' Earnings History.
When will Express Scripts make its next earnings announcement?
What guidance has Express Scripts issued on next quarter's earnings?
Express Scripts updated its FY18 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of $9.27-9.47 for the period, compared to the Thomson Reuters consensus estimate of $8.93. Express Scripts also updated its Q1 guidance to $1.73-1.78 EPS.
Where is Express Scripts' stock going? Where will Express Scripts' stock price be in 2018?
19 analysts have issued 1-year target prices for Express Scripts' stock. Their predictions range from $57.00 to $101.00. On average, they anticipate Express Scripts' share price to reach $82.65 in the next twelve months. View Analyst Ratings for Express Scripts.
What are Wall Street analysts saying about Express Scripts stock?
Here are some recent quotes from research analysts about Express Scripts stock:
- 1. According to Zacks Investment Research, "Integrating medical care and pharmacy benefits under one roof, Express Scripts Holding Company recently announced that it is getting acquired by Cigna Corporation, a global health insurance company.The company has been benefitting from a rise in patient claims and strong customer retention. Express Scripts’ solid guidance for 2018 holds promise. The company recently inked an agreement to acquire eviCore healthcare for $3.6 billion. Express Scripts' pharmacy-benefit management segment (PBM) coupled with eviCore's complementary medical-benefit solutions is likely to build a comprehensive PBM solution worldwide. On the flip side, the company recently announced that its biggest customer and leading health insurer Anthem is not likely to extend its PBM agreement with Express Scripts anymore. Persistent drug pricing issue is also anticipated to affect the stock. The company faces stiff competition." (3/13/2018)
- 2. Maxim Group analysts commented, "Cigna Corp (CI – NR) agreed to acquire ESRX for $54B, with per-share consideration of $48.75 in cash and 0.2434 shares of CI stock. CI also agreed to assume roughly $13B of net debt from ESRX." (3/8/2018)
Are investors shorting Express Scripts?
Express Scripts saw a increase in short interest in the month of February. As of February 28th, there was short interest totalling 24,284,790 shares, an increase of 0.4% from the February 15th total of 24,373,092 shares. Based on an average daily volume of 4,127,635 shares, the short-interest ratio is presently 5.9 days. Approximately 3.6% of the shares of the company are sold short.
Who are some of Express Scripts' key competitors?
Some companies that are related to Express Scripts include Anthem (ANTM), Aetna (AET), Fresenius (FSNUY), Humana (HUM), HCA Healthcare (HCA), Cerner (CERN), Centene (CNC), Quest Diagnostics (DGX), Davita (DVA), Universal Health Services (UHS), Eurofins Scientifi (ERFSF), Nmc Health (NMHLY), WellCare Health Plans (WCG), Icon (ICLR), athenahealth (ATHN), PRA Health Sciences (PRAH), Encompass Health (EHC) and MEDNAX (MD).
Has Express Scripts been receiving favorable news coverage?
News stories about ESRX stock have been trending somewhat positive on Wednesday, according to Accern. The research firm scores the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Express Scripts earned a news sentiment score of 0.21 on Accern's scale. They also assigned media coverage about the company an impact score of 45.43 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Express Scripts' major shareholders?
Express Scripts' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.28%), Barrow Hanley Mewhinney & Strauss LLC (3.02%), Macquarie Group Ltd. (1.80%), Bank of New York Mellon Corp (1.46%), Geode Capital Management LLC (1.17%) and LSV Asset Management (0.87%). Company insiders that own Express Scripts stock include Christine Houston, Christopher A Mcginnis, Everett Neville, Glen D Stettin, Mahon Thomas P Mac, Phyllis S Anderson, Timothy C Wentworth and Woodrow A Myers Jr. View Institutional Ownership Trends for Express Scripts.
Which institutional investors are selling Express Scripts stock?
ESRX stock was sold by a variety of institutional investors in the last quarter, including Barrow Hanley Mewhinney & Strauss LLC, APG Asset Management N.V., BlackRock Inc., Brown Advisory Inc., Macquarie Group Ltd., American Century Companies Inc., Boston Partners and OppenheimerFunds Inc.. Company insiders that have sold Express Scripts company stock in the last year include Christine Houston, Everett Neville, Glen D Stettin, Phyllis S Anderson and Woodrow A Myers Jr. View Insider Buying and Selling for Express Scripts.
Which institutional investors are buying Express Scripts stock?
ESRX stock was acquired by a variety of institutional investors in the last quarter, including Swedbank, ValueAct Holdings L.P., Two Sigma Advisers LP, Arrowstreet Capital Limited Partnership, Two Sigma Investments LP, Bank of New York Mellon Corp, Schroder Investment Management Group and Amundi Pioneer Asset Management Inc.. View Insider Buying and Selling for Express Scripts.
How do I buy shares of Express Scripts?
Shares of ESRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Express Scripts' stock price today?
One share of ESRX stock can currently be purchased for approximately $71.68.
How big of a company is Express Scripts?
Express Scripts has a market capitalization of $40.96 billion and generates $100.06 billion in revenue each year. The company earns $4.52 billion in net income (profit) each year or $7.83 on an earnings per share basis. Express Scripts employs 26,600 workers across the globe.
How can I contact Express Scripts?
Express Scripts' mailing address is ONE EXPRESS WAY, ST. LOUIS MO, 63121. The company can be reached via phone at 314-996-0900 or via email at [email protected]
MarketBeat Community Rating for Express Scripts (ESRX)MarketBeat's community ratings are surveys of what our community members think about Express Scripts and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Express Scripts (NASDAQ:ESRX) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Hold||Hold||Hold|
|Consensus Rating Score: ||2.16||2.17||2.20||2.11|
|Ratings Breakdown: ||2 Sell Rating(s)|
12 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
|4 Sell Rating(s)|
7 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|3 Sell Rating(s)|
10 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|3 Sell Rating(s)|
11 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$82.65||$79.27||$75.38||$68.50|
|Price Target Upside: ||15.31% upside||0.05% downside||1.24% upside||10.47% upside|
Express Scripts (NASDAQ:ESRX) Consensus Price Target History
Express Scripts (NASDAQ:ESRX) Analyst Ratings History
(Data available from 3/21/2016 forward)
Express Scripts (NASDAQ:ESRX) Earnings History and Estimates Chart
Express Scripts (NASDAQ ESRX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/27/2018||Q4 2017||$2.09||$2.16||$25.07 billion||$25.38 billion||View||N/A|
|10/24/2017||Q3 2017||$1.90||$1.90||$25.68 billion||$24.68 billion||View||N/A|
|7/25/2017||Q2 2017||$1.71||$1.73||$25.52 billion||$25.35 billion||View||N/A|
|4/24/2017||Q1 17||$1.32||$1.33||$24.95 billion||$24.65 billion||View||N/A|
|2/14/2017||Q4 2016||$1.87||$1.88||$26.31 billion||$24.90 billion||View||Listen|
|10/25/2016||Q3||$1.74||$1.74||$25.48 billion||$25.41 billion||View||Listen|
|7/25/2016||Q216||$1.57||$1.57||$25.42 billion||$25.20 billion||View||Listen|
|4/25/2016||Q1||$1.22||$1.22||$25.20 billion||$24.80 billion||View||Listen|
|2/16/2016||Q4||$1.56||$1.56||$26.58 billion||$26.18 billion||View||Listen|
|10/27/2015||Q315||$1.44||$1.45||$26.38 million||$25.22 million||View||Listen|
|7/28/2015||Q215||$1.40||$1.44||$26.13 billion||$25.45 billion||View||Listen|
|4/28/2015||Q115||$1.10||$1.10||$24.34 billion||$24.90 billion||View||Listen|
|2/23/2015||Q414||$1.38||$1.39||$25.68 billion||$26.31 billion||View||Listen|
|10/28/2014||Q314||$1.29||$1.29||$24.93 billion||$25.78 billion||View||Listen|
|7/29/2014||Q214||$1.22||$1.23||$24.42 billion||$25.11 billion||View||Listen|
|4/29/2014||Q114||$1.01||$0.99||$23.81 billion||$23.69 billion||View||Listen|
|2/20/2014||Q413||$1.12||$1.12||$25.49 billion||$25.78 billion||View||N/A|
|10/25/2013||Q313||$1.08||$1.08||$25.01 billion||$25.92 billion||View||Listen|
|7/29/2013||Q2 2013||$1.10||$1.12||$25.51 billion||$26.40 billion||View||Listen|
|4/29/2013||Q1 2013||$0.97||$0.99||$25.55 billion||$26.06 billion||View||Listen|
|2/18/2013||Q4 2012||$1.04||$1.05||$27.24 billion||$27.41 billion||View||Listen|
|11/5/2012||Q312||$0.99||$1.02||$27.48 billion||$27.00 billion||View||N/A|
Express Scripts (NASDAQ:ESRX) Earnings Estimates
2018 EPS Consensus Estimate: $9.06
2019 EPS Consensus Estimate: $9.65
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Express Scripts (NASDAQ:ESRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Express Scripts (NASDAQ ESRX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.68%
Institutional Ownership Percentage: 89.44%
Express Scripts (NASDAQ ESRX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/15/2018||Christine Houston||Insider||Sell||19,889||$76.69||$1,525,287.41|| |
|3/1/2018||Everett Neville||VP||Sell||4,895||$75.26||$368,397.70|| |
|1/11/2018||Glen D Stettin||VP||Sell||3,449||$81.00||$279,369.00||33,715|| |
|1/2/2018||Glen D Stettin||VP||Sell||3,448||$76.00||$262,048.00|| |
|12/15/2017||Christine Houston||VP||Sell||10,104||$70.08||$708,088.32||87,400|| |
|11/1/2017||Phyllis S. Anderson||VP||Sell||643||$62.37||$40,103.91|| |
|10/31/2017||Timothy C Wentworth||CEO||Buy||8,000||$61.13||$489,040.00||98,628|| |
|9/11/2017||Woodrow A Myers Jr||Director||Sell||3,900||$63.93||$249,327.00||11,500|| |
|9/8/2017||Phyllis S Anderson||VP||Sell||578||$63.13||$36,489.14||10,530|| |
|8/23/2017||Everett Neville||VP||Sell||1,163||$61.48||$71,501.24||18,232|| |
|5/19/2017||Phyllis S Anderson||VP||Sell||1,100||$60.08||$66,088.00||11,108|| |
|3/1/2017||Everett Neville||SVP||Sell||2,352||$70.16||$165,016.32||11,287|| |
|1/3/2017||Everett Neville||VP||Sell||1,123||$69.41||$77,947.43||12,712|| |
|9/14/2016||Woodrow A Myers Jr||Director||Sell||12,036||$70.40||$847,334.40||14,918|| |
|9/12/2016||Christopher A Mcginnis||VP||Sell||1,785||$70.77||$126,324.45||4,955|| |
|5/10/2016||Everett Neville||VP||Sell||800||$74.11||$59,288.00||13,835|| |
|4/29/2016||Mahon Thomas P Mac||Director||Sell||5,482||$73.93||$405,284.26||55,689|| |
|3/10/2016||Christopher A Mcginnis||VP||Sell||579||$68.56||$39,696.24||6,508|| |
|3/7/2016||Phyllis S Anderson||VP||Sell||614||$71.14||$43,679.96||4,346|| |
|2/29/2016||Everett Neville||VP||Sell||4,323||$71.00||$306,933.00||11,126|| |
|6/9/2015||Gary Wimberly||VP||Sell||1,644||$87.14||$143,258.16|| |
|6/1/2015||Gary Wimberly||VP||Sell||46,069||$86.15||$3,968,844.35|| |
|3/2/2015||Glen D Stettin||VP||Sell||2,674||$84.39||$225,658.86|| |
|2/25/2015||Glen D Stettin||VP||Sell||27,603||$87.55||$2,416,642.65|| |
|12/2/2014||Keith J Ebling||VP||Sell||10,000||$84.25||$842,500.00|| |
|12/1/2014||Steven B Miller||VP||Sell||4,896||$83.57||$409,158.72|| |
|11/28/2014||Glen D Stettin||VP||Sell||10,800||$82.96||$895,968.00|| |
|11/17/2014||John O Parker||Director||Sell||25,822||$78.75||$2,033,482.50|| |
|11/7/2014||Maura C Breen||Director||Sell||13,128||$77.80||$1,021,358.40|| |
|9/5/2014||Edward B Ignaczak||EVP||Sell||9,886||$75.28||$744,218.08|| |
|8/28/2014||Seymour Sternberg||Director||Sell||15,508||$74.12||$1,149,452.96|| |
|8/25/2014||Keith J Ebling||VP||Sell||10,000||$75.50||$755,000.00|| |
|8/5/2014||Gary G Benanav||Director||Sell||12,694||$70.82||$898,989.08|| |
|8/5/2014||Sara E Wade||VP||Sell||20,000||$70.44||$1,408,800.00|| |
|8/4/2014||David A Norton||VP||Sell||1,276||$71.02||$90,621.52|| |
|8/1/2014||Maura C Breen||Director||Sell||12,694||$69.94||$887,818.36|| |
|6/13/2014||George Paz||CEO||Sell||681,508||$71.21||$48,530,184.68|| |
|3/11/2014||Keith Ebling||VP||Sell||25,721||$78.69||$2,023,985.49||22,222|| |
|3/10/2014||Patrick Mcnamee||COO||Sell||68,425||$78.28||$5,356,309.00||12,421|| |
|3/10/2014||Steven Miller||VP||Sell||12,664||$77.96||$987,285.44||21,417|| |
|3/7/2014||Keith Ebling||VP||Sell||295,367||$77.29||$22,828,915.43||28,460|| |
|1/9/2014||Nicholas Lahowchic||Director||Sell||7,650||$72.00||$550,800.00||24,903|| |
|12/26/2013||Nicholas Lahowchic||Director||Sell||12,694||$70.00||$888,580.00||24,903|| |
|11/5/2013||Mahon Thomas Mac||Director||Sell||10,251||$63.20||$647,863.20||39,881|| |
|9/9/2013||Maura C Breen||Director||Sell||10,527||$64.12||$674,991.24|| |
|9/4/2013||Woodrow Myers, Jr.||Director||Sell||7,128||$64.66||$460,896.48||9,698|| |
|7/19/2013||Nicholas Lahowchic||Director||Sell||20,377||$66.26||$1,350,180.02|| |
|6/11/2013||Woodrow A Myers Jr||Director||Sell||1,750||$62.57||$109,497.50|| |
|5/28/2013||Woodrow A Myers Jr||Director||Sell||2,000||$63.75||$127,500.00|| |
|5/15/2013||Jeffrey Hall||CFO||Sell||13,307||$61.13||$813,456.91|| |
|5/8/2013||Woodrow A Myers Jr||Director||Sell||13,462||$61.22||$824,143.64|| |
|5/1/2013||Keith J Ebling||EVP||Sell||59,494||$59.58||$3,544,652.52|| |
|4/30/2013||Patrick Mcnamee||COO||Sell||271,972||$59.65||$16,223,129.80|| |
|3/14/2013||Mahon Thomas P Mac||Director||Buy||5,000||$59.58||$297,900.00|| |
|9/4/2012||Jeffrey Hall||CFO||Sell||75,000||$62.81||$4,710,750.00|| |
|8/8/2012||Edward B Ignaczak||EVP||Sell||115,466||$59.33||$6,850,597.78|| |
Express Scripts (NASDAQ ESRX) News Headlines
Express Scripts (NASDAQ:ESRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Express Scripts (NASDAQ:ESRX) Income Statement, Balance Sheet and Cash Flow Statement
Express Scripts (NASDAQ ESRX) Stock Chart for Wednesday, March, 21, 2018